VIRX News and Press, Viracta Therapeutics Inc. From 11/09/23

Viracta Therapeutics Inc. (VIRX) is expected to report $-0.33 for Q3 2023

Preliminary clinical data from patients with relapsed/refractory EBV + peripheral T-cell lymphoma in the pivotal NAVAL-1 trial demonstrated overall and complete response rates of 40%; follow-up from the Phase 1b/2 study demonstrated median duration of response extended to 17.3 months ...

2023-09-29 15:00:29 ET More on the markets Historical Evidence Between Real Yields Suggests Further Slump For SPY Interest Rates Won't Be Higher For Longer: SPY Implications Rate environment today 'rhymes with 2008' - J.P. Morgan's Kolanovic Stocks in midst o...

SAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that it will host a Research and Development (R&...

Achieved efficacy threshold to advance Epstein-Barr virus-positive (EBV + ) peripheral T-cell lymphoma into Stage 2 becoming the leading indication in pivotal NAVAL-1 study of Nana-val Prioritized EBV + diffuse large B-cell lymphoma and EBV + post-trans...

Results from Phase 1b/2 trial showed complete responses achieved and ongoing durable responses observed out to approximately 36 months across multiple EBV + lymphoma subtypes, including some of the most aggressive cancers All-oral Nana-val was well tolerated, with the most c...

2023-08-07 07:56:44 ET Clinical-stage precision oncology company, Viracta Therapeutics ( NASDAQ: VIRX ) appoints Darrel P. Cohen, M.D., Ph.D. as Chief Medical Officer or CMO, effective immediately. Dr. Cohen has more than 25 years of global clinical research and drug ...

SAN DIEGO, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced the appointment of Darrel P. Cohen, M.D., Ph.D. a...

2023-07-23 04:43:02 ET Summary Shares of precision oncology concern Day One Biopharmaceuticals, Inc. are down over 50% from their 2023 high as Novartis’ combination therapy received first approval for pLGG. However, its lead candidate (tovorafenib) has the potential to trea...

SAN DIEGO, June 28, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that the relapsed or refractory EBV + peripheral T-cell lymp...